Brookwood Investment Group’s VistaShares Target 15 DRUKMacro Distribution ETF DRKY Stock Holding History

Brookwood Investment Group’s Portfolio DRKY Stock Details DRKY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.54M	Sell	122,440 -267,969	-69%	-$5.39M	0.29%	81
2026 Q1	$7.53M	Buy	+390,409	New	+$8.03M	0.93%	13

Other funds holding DRKY

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

MGI

Miller Global Investments Dallas, Texas $121M AUM

OMC

Old Mission Capital Chicago, Illinois $6.31B AUM 20.77% 1-Year Est. Return

Swan Capital Pensacola, Florida $292M AUM 15.76% 1-Year Est. Return

Brookwood Investment Group's DRKY Position: Q2 2026 in Review

Brookwood Investment Group reduced its VistaShares Target 15 DRUKMacro Distribution ETF (DRKY) stake by 69% in Q2 2026, selling an estimated $5.39M and leaving 122,440 shares worth $2.54M. The position accounts for 0.29% of the portfolio, ranked #81.

Brookwood Investment Group first reported a position in DRKY in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.53M in Q1 2026. 5 funds tracked by Wall St. Rank hold DRKY as of Q2 2026.

Brookwood Investment Group held 122,440 shares of VistaShares Target 15 DRUKMacro Distribution ETF worth $2.54M as of Q2 2026.
Brookwood Investment Group sold 267,969 VistaShares Target 15 DRUKMacro Distribution ETF shares in Q2 2026, an estimated $5.39M.
VistaShares Target 15 DRUKMacro Distribution ETF made up 0.29% of Brookwood Investment Group's portfolio in Q2 2026, its #81 holding.
Brookwood Investment Group first reported a position in VistaShares Target 15 DRUKMacro Distribution ETF in Q1 2026 and has held it in 2 quarters since.
Brookwood Investment Group's VistaShares Target 15 DRUKMacro Distribution ETF position peaked at $7.53M in Q1 2026.
5 funds tracked by Wall St. Rank held VistaShares Target 15 DRUKMacro Distribution ETF as of Q2 2026.

Based on Brookwood Investment Group's 13F filing for Q2 2026, filed 23 Jul 2026.